newsfilter
← Latest News
GlobeNewswire·

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – –